IN2015DN00438A - - Google Patents
Info
- Publication number
- IN2015DN00438A IN2015DN00438A IN438DEN2015A IN2015DN00438A IN 2015DN00438 A IN2015DN00438 A IN 2015DN00438A IN 438DEN2015 A IN438DEN2015 A IN 438DEN2015A IN 2015DN00438 A IN2015DN00438 A IN 2015DN00438A
- Authority
- IN
- India
- Prior art keywords
- periodontitis
- present disclosure
- diseases associated
- describes methods
- screening
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/18—Dental and oral disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662022P | 2012-06-20 | 2012-06-20 | |
| US13/801,096 US9579360B2 (en) | 2012-06-20 | 2013-03-13 | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| PCT/US2013/046599 WO2013192319A1 (en) | 2012-06-20 | 2013-06-19 | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00438A true IN2015DN00438A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-06-19 |
Family
ID=49769337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN438DEN2015 IN2015DN00438A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2012-06-20 | 2013-06-19 |
Country Status (8)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2847862C (en) | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| US9579360B2 (en) * | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| MX373962B (es) | 2014-02-25 | 2020-07-13 | Achillion Pharmaceuticals Inc | Compuestos arilo, heteroarilo y heterociclicos para el tratamiento de trastornos mediados por complemento. |
| RS59353B1 (sr) | 2014-06-12 | 2019-10-31 | Ra Pharmaceuticals Inc | Modulacija aktivnosti komplementa |
| HUE056613T2 (hu) | 2015-01-28 | 2022-02-28 | Ra Pharmaceuticals Inc | Komplementaktivitás modulátorai |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AU2016370210A1 (en) | 2015-12-16 | 2018-06-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| WO2018106859A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| PT3985002T (pt) | 2017-03-01 | 2025-08-29 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2019028284A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| EP3720463A1 (en) | 2017-12-04 | 2020-10-14 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
| MA51162A (fr) * | 2017-12-15 | 2020-10-21 | Apellis Pharmaceuticals Inc | Schémas posologiques et compositions et procédés associés |
| BR112020020369A2 (pt) | 2018-04-06 | 2021-01-19 | The Trustees Of The University Of Pennsylvania | Análogos de compstatina com aumento de solubilidade e propriedades farmacocinéticas melhoradas |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| US11807627B2 (en) | 2018-09-25 | 2023-11-07 | Achillon Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
| CA3123583A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| TW202102481A (zh) | 2019-03-29 | 2021-01-16 | 美商Ｒａ製藥公司 | 補體調節劑和相關方法 |
| TW202106290A (zh) | 2019-04-24 | 2021-02-16 | 美商Ｒａ製藥公司 | 用於調節補體活性之組成物及方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270365A (en) | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5627264A (en) * | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| JP2001294536A (ja) * | 2000-04-12 | 2001-10-23 | Sunstar Inc | 歯周病予防・治療剤 |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| PT1928454E (pt) * | 2005-05-10 | 2014-12-04 | Intermune Inc | Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress |
| ES2545775T3 (es) * | 2007-02-05 | 2015-09-15 | Apellis Pharmaceuticals, Inc. | Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| DK2424557T3 (en) * | 2009-05-01 | 2018-01-22 | Univ Pennsylvania | MODIFIED COMPSTATIN WITH PEPTID BACKBONE AND C-TERMINAL MODIFICATIONS |
| WO2010132954A1 (en) | 2009-05-21 | 2010-11-25 | Oral Health Australia Pty Ltd | Method of treating periodontal disease by administering antagonists of par-2 |
| US8642614B2 (en) * | 2009-09-23 | 2014-02-04 | The Regents Of The University Of Colorado, A Body Corporate | Toll-like receptor modulators and uses thereof |
| AU2011207441A1 (en) | 2010-01-22 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| JP5961809B2 (ja) * | 2010-03-17 | 2016-08-02 | 国立大学法人 鹿児島大学 | 歯周病特異的ペプチド、並びにそれを用いた歯周病の治療および診断 |
| MX379206B (es) * | 2011-06-22 | 2025-03-10 | Apellis Pharmaceuticals Inc | Uso de inhibidores del complemento en trastornos crónicos. |
| CA2847862C (en) * | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| US9579360B2 (en) * | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
-
2013
- 2013-03-13 US US13/801,096 patent/US9579360B2/en active Active
- 2013-06-19 AU AU2013277217A patent/AU2013277217B2/en active Active
- 2013-06-19 JP JP2015518554A patent/JP6363595B2/ja active Active
- 2013-06-19 EP EP13807873.8A patent/EP2863949B1/en active Active
- 2013-06-19 CA CA2877299A patent/CA2877299C/en active Active
- 2013-06-19 CN CN201380032526.1A patent/CN104640567A/zh active Pending
- 2013-06-19 IN IN438DEN2015 patent/IN2015DN00438A/en unknown
- 2013-06-19 WO PCT/US2013/046599 patent/WO2013192319A1/en not_active Ceased
-
2017
- 2017-01-27 US US15/418,441 patent/US10668135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013192319A1 (en) | 2013-12-27 |
| US9579360B2 (en) | 2017-02-28 |
| AU2013277217A2 (en) | 2015-01-22 |
| CN104640567A (zh) | 2015-05-20 |
| JP2015523999A (ja) | 2015-08-20 |
| AU2013277217A1 (en) | 2015-01-22 |
| US10668135B2 (en) | 2020-06-02 |
| EP2863949A1 (en) | 2015-04-29 |
| JP6363595B2 (ja) | 2018-07-25 |
| CA2877299A1 (en) | 2013-12-27 |
| AU2013277217B2 (en) | 2018-03-08 |
| EP2863949B1 (en) | 2019-01-23 |
| US20130344082A1 (en) | 2013-12-26 |
| EP2863949A4 (en) | 2016-03-02 |
| CA2877299C (en) | 2022-07-12 |
| US20170202935A1 (en) | 2017-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00438A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO2011091366A3 (en) | Methods of treating or preventing periodontitis and diseases associated with periodontitis | |
| MX365614B (es) | Composiciones utiles para tratar trastornos relacionados con kit. | |
| PH12016502167A1 (en) | Hdl theraphy markers | |
| GB201103062D0 (en) | Method | |
| EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
| MX2014010481A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| JOP20140141B1 (ar) | استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية | |
| WO2014165090A8 (en) | Compounds for the treatment of tuberculosis | |
| IN2014DN06792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX2021011946A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| PL3082831T3 (pl) | Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| MX2020002544A (es) | Sales de glicopirrolato. | |
| EP3065768A4 (en) | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| PL2792364T3 (pl) | Kompozycja do zapobiegania lub do leczenia kaca | |
| MX2015007518A (es) | Metodos para tratar el prurito. | |
| MY180834A (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| MX2013007603A (es) | Antagonistas de hedgehog que tienen residuos que se unen al zinc. | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| IN2014DN06738A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. |